Beurs gesloten -
Andere beurzen
|
Variatie 5 dagen | Verschil t.o.v. 1 jan (%) | ||
2,39 USD | +9,13% | +20,10% | -64,51% |
Omzet 2024 * | 25,22 mln. 23,67 mln. | Omzet 2025 * | 32,65 mln. 30,65 mln. | Marktkapitalisatie | 3,54 mln. 3,32 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | -24 mln. -22,53 mln. | Nettowinst (verlies) 2025 * | -9 mln. -8,45 mln. | EV/omzet 2024 * | 0,14 x |
Nettoliquiditeiten 2024 * | - 0 | Nettoliquiditeiten 2025 * | - 0 | EV/omzet 2025 * | 0,11 x |
K/w-verhouding 2024 * |
-0,15
x | K/w-verhouding 2025 * |
-0,66
x | Werknemers | 25 |
Dividendrendement 2024 * |
-
| Dividendrendement 2025 * |
-
| Vrij verhandelbaar | 88,21% |
Recentste transcriptie over Eiger BioPharmaceuticals, Inc.
1 dag | +9,13% | ||
1 week | +20,10% | ||
Lopende maand | -52,25% | ||
1 maand | -50,31% | ||
3 maanden | -64,54% | ||
6 maanden | -70,78% | ||
Lopend jaar | -64,51% |
Managers | Titel | Leeftijd | Van |
---|---|---|---|
David Apelian
CEO | Chief Executive Officer | 59 | 14-06-17 |
Director of Finance/CFO | 58 | 13-04-23 | |
James Vollins
CMP | Compliance Officer | 55 | 13-04-23 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Director/Board Member | 57 | 18-07-22 | |
Thomas Dietz
CHM | Chairman | 60 | 22-03-16 |
David Apelian
CEO | Chief Executive Officer | 59 | 14-06-17 |
Naam | Gewicht | Volume | Vaira. 1 jan. | belegger rating |
---|---|---|---|---|
0.03% | 0 M€ | 0,00% | - | |
0.00% | 18 M€ | +2,79% | - |
Datum | Koers | Variatie | Volume |
---|---|---|---|
19-04-24 | 2,39 | +9,13% | 141 623 |
18-04-24 | 2,19 | +3,79% | 27 345 |
17-04-24 | 2,11 | -6,22% | 11 382 |
16-04-24 | 2,25 | -5,06% | 20 184 |
15-04-24 | 2,37 | +19,10% | 123 305 |
uitgestelde koers OTC Markets, 19 april 2024 om 21:57 uur
Meer koersenHerzieningen van WPA
Vaira. 1 jan. | Kapi. | |
---|---|---|
-64,51% | 3,54 mln. | |
-1,42% | 41,52 mld. | |
+42,15% | 39,9 mld. | |
+1,97% | 38,83 mld. | |
-14,19% | 26,05 mld. | |
+1,82% | 23,78 mld. | |
-24,55% | 18,26 mld. | |
-4,07% | 11,65 mld. | |
+21,36% | 11,53 mld. | |
+8,20% | 11,2 mld. |